ClinicalTrials.gg
CompletedNCT04790370HI-PEITHOUpdated Nov 16, 2026Results posted

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

A Phase 4 interventional study of Anticoagulation with heparin and EkoSonicTM Endovascular System in Pulmonary Embolism, sponsored by Boston Scientific Corporation. Completed at 60 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Boston Scientific Corporation · Phase 4, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now CompletedResults posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
544
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.

Enrollment
41st of 166
544 · median 142
Started
2021
with 9 others
Phase 4
21 of 236
2 open now
Registered
170th of 236
by date
Lead sponsor
5 of 236
Boston Scientific Corporation

Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 41st largest by enrollment of the 166 interventional ones that give a count, is one of 10 that started in 2021, is one of 21 in phase 4, and was the 170th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Pulmonary Embolism with a site in United States, or all of them as a file.
02

Study summary

There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE.

Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after randomization and have assessments while in the hospital as well as at 7 days, 30 days, 6 months and 12 months after randomization. The study will try to find out if one of these treatments is better than the other at reducing the risk of death and other serious problems.

Read the detailed description

This study will assess whether ultrasound-facilitated, catheter-directed thrombolysis and standard anticoagulation are associated with a significant reduction in the composite outcome of pulmonary embolism (PE)-related mortality, cardiorespiratory decompensation or collapse, or nonfatal symptomatic and objectively confirmed recurrence of PE compared to anticoagulation alone within seven days of randomization

The HI-PEITHO study has been designed to address the important gaps in clinical evidence by comparing the clinical benefit of the ultrasound-facilitated local delivery of a low dose thrombolytic agent and anticoagulation with those of anticoagulation alone in patients with intermediate-high risk PE at a higher estimated risk of early decompensation based on clinical parameters at presentation.

This study has a focus on improving the safety of thrombolysis and advancing the concept of intermediate-high risk and the PE severity criteria, to better identify patients who may clinically benefit from thrombolysis.

The results of this study will contribute further evidence to the existing data on the treatment and outcomes of acute, intermediate-high risk PE and provide controlled data related to catheter-based interventions.

Data will be entered by the site into an electronic database. The database will include data checks to compare data entered into the database against predefined rules for ranges and consistency with other data fields in the database.

Site monitoring will take place with source data verification to assess the accuracy and completeness of registry data by comparing the data to medical records and study assessments.

03

Conditions studied

  • Pulmonary Embolism

Browse trials for

Keywords

  • Acute intermediate-high risk pulmonary embolism
  • Ultrasound-facilitated, catheter-directed thrombolysis
  • Thrombolysis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years, inclusive
  • Objectively confirmed acute PE, based on computed tomography pulmonary angiography (CTPA) showing a filling defect in at least one main or proximal lobar pulmonary artery
  • Elevated risk of early death/hemodynamic collapse, indicated by at least two of the following new-onset clinical criteria:

    1. -documented tachycardia with heart rate ≥100 beats per minute, not due to hypovolemia, arrhythmia, or sepsis;
    2. SBP ≤ 110 mm Hg for at least 15 minutes;
    3. respiratory rate > 20 x min\^-1 or oxygen saturation on pulse oximetry (SpO2) \< 90% (or partial arterial oxygen pressure \< 60 mmHg) at rest while breathing room air;
  • Right-to-left ventricular (RV/LV) diameter ratio ≥ 1.0 on CTPA
  • Serum troponin I or T levels above the
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability*, i.e. at least one of the following present:

    1. cardiac arrest or need for cardiopulmonary resuscitation;
    2. need for ECMO, or ECMO initiated before randomization
    3. PE-related shock, defined as: (i) SBP \< 90 mmHg, or vasopressors required to achieve SBP ≥ 90 mmHg, despite an adequate volume status; and (ii) end-organ hypoperfusion (altered mental status; oliguria/anuria; increased serum lactate);
    4. isolated persistent hypotension (SBP \< 90 mmHg, or a systolic pressure drop by at least 40 mmHg for at least 15 minutes), not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who presented with temporary need for fluid resuscitation and/or low-dose catecholamines may be included, provided that they could be stabilized within 2 hours of admission and maintain SBP of ≥ 90 mmHg and adequate organ perfusion without catecholamine infusion.
  • Need for admission to an intensive care unit for a reason other than the index PE episode. NB: Patients who test positive for SARS-CoV-2 can be enrolled where the investigator believes that the pulmonary embolism is the dominant pathology in the patient's clinical presentation and qualifying cardiorespiratory parameters.
  • Temperature above 39 degrees C / 102.2 degrees F
  • Logistical reasons limiting the rapid availability of interventional procedures to treat acute PE (e.g., during the outbreak of an epidemic)
  • Index PE symptom duration > 14 days
  • Active bleeding
  • History of intracranial or intraocular bleeding at any time
  • Stroke or within the past 6 months, or previous stroke at any time if associated with permanent disability
  • Central nervous system neoplasm, or cancer
  • Major neurologic, ophthalmologic, abdominal, cardiac, thoracic, vascular or orthopedic surgery or trauma (including syncope-associated with head strike or skeletal fracture) within the past 3 weeks
  • count \< 100 x 10\^9 x L\^-1
  • Patients who have received a once-daily therapeutic dose of LMWH or a therapeutic dose of fondaparinux within 24 hours prior to randomization
  • Patients who have received one of the direct oral anticoagulants apixaban or rivaroxaban within 12 hours prior to randomization
  • Patients who have received one of the direct oral anticoagulants dabigatran or edoxaban for the index PE episode, as these drugs are not approved for patients who have not received heparin for at least 5 days
  • Administration of a thrombolytic agent or a glycoprotein IIb/IIIa receptor antagonist during the current hospital stay and/or within 30 days, for any reason
  • Chronic treatment with antiplatelet agents other than low-dose acetylsalicylic acid or clopidogrel 75 mg once daily (but not both). Dual antiplatelet therapy is excluded.
  • Chronic treatment with a direct oral anticoagulant (apixaban, dabigatran, edoxaban or rivaroxaban)
  • Chronic treatment with a vitamin K antagonist, or known coagulopathy including severe hepatic dysfunction, with an (INR) > 1.5
  • Pregnancy or lactation
  • Previous inclusion in the study
  • Known to alteplase, LMWH or UFH, or to any of the
  • less than 6 months
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
544 participants (actual)

Study arms

  • Active comparator
    Anticoagulation

    Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)

    Drug: Anticoagulation with heparin

  • Active comparator
    Anticoagulation and EkoSonicTM Endovascular System

    Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]

    Drug: Anticoagulation with heparin · Device: EkoSonicTM Endovascular System

Interventions

  • DrugAnticoagulation with heparin

    Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)

    Also known as: heparin, LMWH, UFH, anticoag, antiplatelet

  • DeviceEkoSonicTM Endovascular System

    EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]

    Also known as: EKOS, USCDT, CDT, thrombolysis, fibrinolysis

06

What researchers measure

Primary outcomes

  1. Number of Participants With PE-Related Mortality

    Death resulting from pulmonary embolism occurring within the assessment period.

    Time frame: Within seven days of randomization

  2. Number of Participants With Recurrent Pulmonary Embolism

    Symptomatic, objectively confirmed, nonfatal recurrent pulmonary embolism occurring during the assessment period.

    Time frame: Within seven days of randomization

  3. Number of Participants With Cardiorespiratory Decompensation or Collapse

    Cardiorespiratory collapse or decompensation is defined as at least one of the following criteria: 1. cardiac arrest or need for CPR at any time between randomization and day 7; 2. signs of shock: new-onset persistent arterial hypotension (systolic blood pressure (SBP) below 90 mmHg or SBP drop by at least 40 mm Hg, over at least 15 minutes and despite an adequate volume status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7; 3. placement on extracorporeal membrane oxygenation (ECMO) at any time between randomization and day 7; 4. intubation, or initiation of noninvasive mechanical ventilation at any time between randomization and day 7; 5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements taken twice, 15 minutes apart.

    Time frame: Within seven days of randomization

Other outcomes

  1. Change From Baseline in Right Ventricular-to-Left Ventricular (RV-to-LV) Diameter Ratio

    The RV-to-LV diameter ratio was assessed by echocardiography at baseline and 48 hours after the index procedure. The ratio was calculated by dividing the right ventricular diameter by the left ventricular diameter. Change from baseline was defined as the difference between the 48-hour and baseline measurements. Higher RV-to-LV ratios indicate greater right ventricular dilation, whereas lower ratios indicate less right ventricular dilation and improvement in right ventricular size relative to the left ventricle.

    Time frame: Baseline and 48 hours after the index procedure

  2. Number of Participants With Cardiorespiratory Decompensation

    The number of participants who experienced cardiorespiratory decompensation within 7 days of randomization. Cardiorespiratory decompensation was defined as the occurrence of any of the following: cardiac arrest or receipt of cardiopulmonary resuscitation (CPR), signs of shock, placement on extracorporeal membrane oxygenation (ECMO), intubation or initiation of non-invasive mechanical ventilation, or a National Early Warning Score (NEWS) of 9 or greater. Participants were counted once if they experienced one or more of these events during the 7-day assessment period.

    Time frame: Within seven days of randomization

  3. Number of Participants With GUSTO Major (Moderate or Severe) Bleeding

    Major bleeding will be adjudicated according to the GUSTO criteria: 1. GUSTO severe or life-threatening bleeding: A bleeding episode that leads to hemodynamic compromise requiring emergency intervention (such as replacement of fluid and/or blood products, inotropic support, or surgical treatment), or is life-threatening or fatal. 2. GUSTO moderate bleeding (a bleeding episode requiring blood transfusion(s), but which is not deemed life-threatening and does not lead to hemodynamic compromise requiring emergency fluid replacement, inotropic support, or interventional treatment).

    Time frame: Within seven days of randomization

  4. Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding

    Major bleeding will also be adjudicated according to the ISTH criteria: 1. Fatal bleeding and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome) and/or 3. Bleeding causing a fall in hemoglobin level of 20 g/L (2 g/dL) or more, or leading to transfusion of two or more units of whole blood or red blood cells.

    Time frame: Within 7 days, 30 days, and 6 months of randomization

  5. Number of Participants With Ischemic or Hemorrhagic Stroke

    Occurrence of ischemic or hemorrhagic stroke during the assessment period. Participants were counted once for each assessment time point if an ischemic or hemorrhagic stroke occurred.

    Time frame: Within 7 days and 30 days following randomization

  6. Number of Participants With All-Cause Mortality

    Death from any cause.

    Time frame: Within 7 days, 30 days, 6 months, and 12 months of randomization

  7. Number of Participants With at Least One Serious Adverse Event

    Number of participants who experienced at least one serious adverse event.

    Time frame: Within 30 days of randomization

  8. Number of Participants With All-Cause Mortality, Cardiorespiratory Collapse or Decompensation, or Recurrent Pulmonary Embolism

    Death due to any cause, Cardiorespiratory collapse or decompensation should fulfill at least one of the following criteria: 1. cardiac arrest or need for CPR at any time between randomization and day 7; 2. signs of shock: new-onset persistent arterial hypotension (SBP below 90 mmHg or SBP drop by at least 40 mmHg over at least 15 minutes, and despite an adequate filling status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7; 3. placement on ECMO at any time between randomization and day 7; 4. intubation, or initiation of non-invasive mechanical ventilation at any time between randomization and day 7; 5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements, taken twice.

    Time frame: Within 30 days of randomization

  9. Number of Participants With Symptomatic Recurrent Pulmonary Embolism

    Number of participants who experienced symptomatic recurrent pulmonary embolism.

    Time frame: Within 30 days and 6 months of randomization

  10. Change From Baseline in RV Dysfunction on Echocardiography

    Right ventricle to left ventricle end diastolic diameter ratio (RV/LV).

    Time frame: 6 months

  11. Duration of Hospitalization for the Index Pulmonary Embolism Event

    Length of hospital stay was calculated as the number of days between hospital admission and hospital discharge.

    Time frame: Within 30 days of randomization

  12. Duration of Stay in the Intensive Care Unit (ICU), Intermediate Care Unit, or Coronary Care Unit for the Index Pulmonary Embolism Event

    Length of stay was calculated as the time between admission to and discharge from the intensive care unit (ICU), intermediate care unit, or coronary care unit during hospitalization.

    Time frame: Within 30 days of randomization

  13. Functional Status as Measured by World Health Organization (WHO) Functional Class

    WHO Functional Class categorizes symptom severity and physical activity limitation. Class I indicates no limitation of physical activity; Class II indicates slight limitation of physical activity; Class III indicates marked limitation of physical activity; and Class IV indicates inability to perform physical activity without symptoms, with symptoms that may be present at rest. Lower classes (I-II) represent better functional status, whereas higher classes (III-IV) represent worse functional status. Participants were classified according to WHO Functional Class at each assessment time point.

    Time frame: Up to 7 days, 30 days, 6 and 12 months of randomization

  14. Functional Status as Measured by 6-Minute Walk Test (6MWT)

    The 6MWT measures the distance a patient can walk on a flat surface in a period of 6 minutes. A 100-meter distance is measured in a hallway, and the patient is asked to walk quickly as many laps as they can over the course of the timed test. Greater distances indicate better functional exercise capacity, whereas shorter distances indicate greater functional limitation. The total distance is measured. The patient's baseline vitals and symptoms are compared to their condition at the completion of the test.

    Time frame: 30 days, 6 months, and 12 months of randomization

  15. Functional Status as Measured by Post-Venous Thromboembolism Functional Status (PVFS) Scale

    The Post-Venous Thromboembolism Functional Status (PVFS) Scale assesses functional limitations following a venous thromboembolic event. Participants are classified according to the following grades: Grade 0 = no functional limitations or symptoms; Grade 1 = symptoms present but no limitations in usual activities; Grade 2 = slight functional limitations requiring occasional modification of activities; Grade 3 = moderate functional limitations requiring regular modification of activities; Grade 4 = severe functional limitations with inability to perform usual activities without assistance; Grade 5 = death. Lower grades (0-1) indicate better functional status and less disability, while higher grades (3-4) indicate worse functional status and greater disability. Participants were assessed at each study time point and classified according to the PVFS grade that best described their functional status.

    Time frame: 30 days, 6 months, and 12 months of randomization

  16. Quality of Life Using PEmb-QOL

    PEmb-QOL is a questionnaire that assesses post-pulmonary embolism quality of life in the context of pulmonary-specific symptoms. The PEmb-QOL questionnaire contains six dimensions based on the contents of the items: frequency of complaints, limitations in activities of daily living, work-related problems, social limitations, intensity of complaints and emotional complaints. Higher scores indicate worse outcome.

    Time frame: 6 and 12 months

  17. Quality of Life Using SF-36

    The SF-36 questionnaire is a generic quality of life measure containing eight health domains (physical functioning, physical role, pain, general health, vitality, social function, emotional role functioning, and mental health). The scoring is on a 0-100 scale, with a higher score indicating better health. Scores are combined into two overall summary scores: physical health summary score and mental health summary score.

    Time frame: 6 and 12 months

  18. Quality of Life Using EQ-5D Scale

    The EQ-5D is a patient reported outcome that provides a simple descriptive profile and single index value for health status. The questionnaire consists of 5 questions pertaining to specific health dimensions, including mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health status rating scale.

    Time frame: 6 and 12 months

  19. Diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

    CTEPH will be diagnosed by the investigational site according to presence of all of the following criteria: 1. At least one mismatched segmental perfusion defect demonstrated by ventilation/perfusion scanning after 3 months of adequate therapeutic anticoagulation 2. Resting mean pulmonary arterial pressure (mPAP) ≥25 mmHg measured by invasive right heart catheterization 3. Pulmonary capillary wedge pressure ≤15 mmHg.

    Time frame: Within 12 months

07

Results

Posted Nov 16, 2026

Participant flow

7 day
Participant flow — 7 day
MilestoneAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Started271273
Completed266266
Not completed57
30 day
Participant flow — 30 day
MilestoneAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Started271273
Completed250253
Not completed2120

Outcome measures

PrimaryNumber of Participants With PE-Related Mortality

Death resulting from pulmonary embolism occurring within the assessment period.

Time frame:
Within seven days of randomization
Reported as:
Count of participants · Participants
Number of Participants With PE-Related Mortality
ParticipantsAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Number of Participants With PE-Related Mortality13
PrimaryNumber of Participants With Recurrent Pulmonary Embolism

Symptomatic, objectively confirmed, nonfatal recurrent pulmonary embolism occurring during the assessment period.

Time frame:
Within seven days of randomization
Reported as:
Count of participants · Participants
Number of Participants With Recurrent Pulmonary Embolism
ParticipantsAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Number of Participants With Recurrent Pulmonary Embolism11
PrimaryNumber of Participants With Cardiorespiratory Decompensation or Collapse

Cardiorespiratory collapse or decompensation is defined as at least one of the following criteria: 1. cardiac arrest or need for CPR at any time between randomization and day 7; 2. signs of shock: new-onset persistent arterial hypotension (systolic blood pressure (SBP) below 90 mmHg or SBP drop by at least 40 mm Hg, over at least 15 minutes and despite an adequate volume status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7; 3. placement on extracorporeal membrane oxygenation (ECMO) at any time between randomization and day 7; 4. intubation, or initiation of noninvasive mechanical ventilation at any time between randomization and day 7; 5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements taken twice, 15 minutes apart.

Time frame:
Within seven days of randomization
Reported as:
Count of participants · Participants
Number of Participants With Cardiorespiratory Decompensation or Collapse
ParticipantsAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Number of Participants With Cardiorespiratory Decompensation or Collapse2810
Other pre-specifiedChange From Baseline in Right Ventricular-to-Left Ventricular (RV-to-LV) Diameter Ratio

The RV-to-LV diameter ratio was assessed by echocardiography at baseline and 48 hours after the index procedure. The ratio was calculated by dividing the right ventricular diameter by the left ventricular diameter. Change from baseline was defined as the difference between the 48-hour and baseline measurements. Higher RV-to-LV ratios indicate greater right ventricular dilation, whereas lower ratios indicate less right ventricular dilation and improvement in right ventricular size relative to the left ventricle.

Time frame:
Baseline and 48 hours after the index procedure
Reported as:
Mean · Ratio
Change From Baseline in Right Ventricular-to-Left Ventricular (RV-to-LV) Diameter Ratio
RatioAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Change From Baseline in Right Ventricular-to-Left Ventricular (RV-to-LV) Diameter Ratio-0.27 ± .23-0.38 ± 0.24
Other pre-specifiedNumber of Participants With Cardiorespiratory Decompensation

The number of participants who experienced cardiorespiratory decompensation within 7 days of randomization. Cardiorespiratory decompensation was defined as the occurrence of any of the following: cardiac arrest or receipt of cardiopulmonary resuscitation (CPR), signs of shock, placement on extracorporeal membrane oxygenation (ECMO), intubation or initiation of non-invasive mechanical ventilation, or a National Early Warning Score (NEWS) of 9 or greater. Participants were counted once if they experienced one or more of these events during the 7-day assessment period.

Time frame:
Within seven days of randomization
Reported as:
Count of participants · Participants
Number of Participants With Cardiorespiratory Decompensation
ParticipantsAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Cardiac arrest or cardiopulmonary resuscitation46
Signs of shock95
Placement on ECMO31
Intubation or non-invasive mechanical ventilation56
National Early Warning Score ≥9192
Other pre-specifiedNumber of Participants With GUSTO Major (Moderate or Severe) Bleeding

Major bleeding will be adjudicated according to the GUSTO criteria: 1. GUSTO severe or life-threatening bleeding: A bleeding episode that leads to hemodynamic compromise requiring emergency intervention (such as replacement of fluid and/or blood products, inotropic support, or surgical treatment), or is life-threatening or fatal. 2. GUSTO moderate bleeding (a bleeding episode requiring blood transfusion(s), but which is not deemed life-threatening and does not lead to hemodynamic compromise requiring emergency fluid replacement, inotropic support, or interventional treatment).

Time frame:
Within seven days of randomization
Reported as:
Count of participants · Participants
Number of Participants With GUSTO Major (Moderate or Severe) Bleeding
ParticipantsAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Number of Participants With GUSTO Major (Moderate or Severe) Bleeding49
Other pre-specifiedNumber of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding

Major bleeding will also be adjudicated according to the ISTH criteria: 1. Fatal bleeding and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome) and/or 3. Bleeding causing a fall in hemoglobin level of 20 g/L (2 g/dL) or more, or leading to transfusion of two or more units of whole blood or red blood cells.

Time frame:
Within 7 days, 30 days, and 6 months of randomization

Results for this outcome have not been posted.

Other pre-specifiedNumber of Participants With Ischemic or Hemorrhagic Stroke

Occurrence of ischemic or hemorrhagic stroke during the assessment period. Participants were counted once for each assessment time point if an ischemic or hemorrhagic stroke occurred.

Time frame:
Within 7 days and 30 days following randomization
Reported as:
Count of participants · Participants
Number of Participants With Ischemic or Hemorrhagic Stroke
ParticipantsAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Ischemic Stroke within 7 days01
Ischemic Stroke within 30 days01
Intracranial hemorrhage within 7 days00
Intracranial hemorrhage within 30 days00
Other pre-specifiedNumber of Participants With All-Cause Mortality

Death from any cause.

Time frame:
Within 7 days, 30 days, 6 months, and 12 months of randomization

Results for this outcome have not been posted.

Other pre-specifiedNumber of Participants With at Least One Serious Adverse Event

Number of participants who experienced at least one serious adverse event.

Time frame:
Within 30 days of randomization
Reported as:
Count of participants · Participants
Number of Participants With at Least One Serious Adverse Event
ParticipantsAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Number of Participants With at Least One Serious Adverse Event4442
Other pre-specifiedNumber of Participants With All-Cause Mortality, Cardiorespiratory Collapse or Decompensation, or Recurrent Pulmonary Embolism

Death due to any cause, Cardiorespiratory collapse or decompensation should fulfill at least one of the following criteria: 1. cardiac arrest or need for CPR at any time between randomization and day 7; 2. signs of shock: new-onset persistent arterial hypotension (SBP below 90 mmHg or SBP drop by at least 40 mmHg over at least 15 minutes, and despite an adequate filling status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7; 3. placement on ECMO at any time between randomization and day 7; 4. intubation, or initiation of non-invasive mechanical ventilation at any time between randomization and day 7; 5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements, taken twice.

Time frame:
Within 30 days of randomization
Reported as:
Count of participants · Participants
Number of Participants With All-Cause Mortality, Cardiorespiratory Collapse or Decompensation, or Recurrent Pulmonary Embolism
ParticipantsAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Number of Participants With All-Cause Mortality, Cardiorespiratory Collapse or Decompensation, or Recurrent Pulmonary Embolism3012
Other pre-specifiedNumber of Participants With Symptomatic Recurrent Pulmonary Embolism

Number of participants who experienced symptomatic recurrent pulmonary embolism.

Time frame:
Within 30 days and 6 months of randomization

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in RV Dysfunction on Echocardiography

Right ventricle to left ventricle end diastolic diameter ratio (RV/LV).

Time frame:
6 months

Results for this outcome have not been posted.

Other pre-specifiedDuration of Hospitalization for the Index Pulmonary Embolism Event

Length of hospital stay was calculated as the number of days between hospital admission and hospital discharge.

Time frame:
Within 30 days of randomization
Reported as:
Mean · Mean number of days
Duration of Hospitalization for the Index Pulmonary Embolism Event
Mean number of daysAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Duration of Hospitalization for the Index Pulmonary Embolism Event6.48 ± 4.885.77 ± 5.02
Other pre-specifiedDuration of Stay in the Intensive Care Unit (ICU), Intermediate Care Unit, or Coronary Care Unit for the Index Pulmonary Embolism Event

Length of stay was calculated as the time between admission to and discharge from the intensive care unit (ICU), intermediate care unit, or coronary care unit during hospitalization.

Time frame:
Within 30 days of randomization
Reported as:
Mean · Mean number of days
Duration of Stay in the Intensive Care Unit (ICU), Intermediate Care Unit, or Coronary Care Unit for the Index Pulmonary Embolism Event
Mean number of daysAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Duration of Stay in the Intensive Care Unit (ICU), Intermediate Care Unit, or Coronary Care Unit for the Index Pulmonary Embolism Event2.78 ± 3.092.19 ± 3.02
Other pre-specifiedFunctional Status as Measured by World Health Organization (WHO) Functional Class

WHO Functional Class categorizes symptom severity and physical activity limitation. Class I indicates no limitation of physical activity; Class II indicates slight limitation of physical activity; Class III indicates marked limitation of physical activity; and Class IV indicates inability to perform physical activity without symptoms, with symptoms that may be present at rest. Lower classes (I-II) represent better functional status, whereas higher classes (III-IV) represent worse functional status. Participants were classified according to WHO Functional Class at each assessment time point.

Time frame:
Up to 7 days, 30 days, 6 and 12 months of randomization

Results for this outcome have not been posted.

Other pre-specifiedFunctional Status as Measured by 6-Minute Walk Test (6MWT)

The 6MWT measures the distance a patient can walk on a flat surface in a period of 6 minutes. A 100-meter distance is measured in a hallway, and the patient is asked to walk quickly as many laps as they can over the course of the timed test. Greater distances indicate better functional exercise capacity, whereas shorter distances indicate greater functional limitation. The total distance is measured. The patient's baseline vitals and symptoms are compared to their condition at the completion of the test.

Time frame:
30 days, 6 months, and 12 months of randomization

Results for this outcome have not been posted.

Other pre-specifiedFunctional Status as Measured by Post-Venous Thromboembolism Functional Status (PVFS) Scale

The Post-Venous Thromboembolism Functional Status (PVFS) Scale assesses functional limitations following a venous thromboembolic event. Participants are classified according to the following grades: Grade 0 = no functional limitations or symptoms; Grade 1 = symptoms present but no limitations in usual activities; Grade 2 = slight functional limitations requiring occasional modification of activities; Grade 3 = moderate functional limitations requiring regular modification of activities; Grade 4 = severe functional limitations with inability to perform usual activities without assistance; Grade 5 = death. Lower grades (0-1) indicate better functional status and less disability, while higher grades (3-4) indicate worse functional status and greater disability. Participants were assessed at each study time point and classified according to the PVFS grade that best described their functional status.

Time frame:
30 days, 6 months, and 12 months of randomization

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life Using PEmb-QOL

PEmb-QOL is a questionnaire that assesses post-pulmonary embolism quality of life in the context of pulmonary-specific symptoms. The PEmb-QOL questionnaire contains six dimensions based on the contents of the items: frequency of complaints, limitations in activities of daily living, work-related problems, social limitations, intensity of complaints and emotional complaints. Higher scores indicate worse outcome.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life Using SF-36

The SF-36 questionnaire is a generic quality of life measure containing eight health domains (physical functioning, physical role, pain, general health, vitality, social function, emotional role functioning, and mental health). The scoring is on a 0-100 scale, with a higher score indicating better health. Scores are combined into two overall summary scores: physical health summary score and mental health summary score.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life Using EQ-5D Scale

The EQ-5D is a patient reported outcome that provides a simple descriptive profile and single index value for health status. The questionnaire consists of 5 questions pertaining to specific health dimensions, including mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health status rating scale.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

Other pre-specifiedDiagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

CTEPH will be diagnosed by the investigational site according to presence of all of the following criteria: 1. At least one mismatched segmental perfusion defect demonstrated by ventilation/perfusion scanning after 3 months of adequate therapeutic anticoagulation 2. Resting mean pulmonary arterial pressure (mPAP) ≥25 mmHg measured by invasive right heart catheterization 3. Pulmonary capillary wedge pressure ≤15 mmHg.

Time frame:
Within 12 months

Results for this outcome have not been posted.

Adverse events

Collected over Through 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anticoagulation3/271 (1.1%)44/271 (16.2%)6/271 (2.2%)
Anticoagulation and EkoSonicTM Endovascular System6/273 (2.2%)42/273 (15.4%)16/273 (5.9%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
Cardiopulmonary failureCardiac disorders12/2712/273
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/2714/273
Haemodynamic instabilityVascular disorders4/2711/273
PneumoniaInfections and infestations4/2713/273
Cardiac arrestCardiac disorders2/2712/273
Cardio-respiratory arrestCardiac disorders2/2711/273
HypotensionVascular disorders2/2711/273
HypoxiaRespiratory, thoracic and mediastinal disorders2/2710/273
Respiratory failureRespiratory, thoracic and mediastinal disorders2/2710/273
Atrial fibrillationCardiac disorders2/2711/273
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAnticoagulationAnticoagulation and EkoSonicTM Endovascular System
AnaemiaBlood and lymphatic system disorders3/2710/273
Catheter site haemorrhageGeneral disorders0/2712/273
Vascular access site haematomaInjury, poisoning and procedural complications0/2712/273
HaematomaVascular disorders0/2712/273
HaematuriaRenal and urinary disorders0/2712/273
Puncture site haemorrhageGeneral disorders1/2710/273
DizzinessNervous system disorders1/2710/273
EpistaxisRespiratory, thoracic and mediastinal disorders1/2711/273
C-reactive protein increasedInvestigations1/2710/273
Splenic infarctionBlood and lymphatic system disorders0/2711/273

Baseline characteristics

Age, Customized
Age, Customized(Years)AnticoagulationAnticoagulation and EkoSonicTM Endovascular SystemTotal
Age (years)58.2 ± 13.458.2 ± 13.658.2 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)AnticoagulationAnticoagulation and EkoSonicTM Endovascular SystemTotal
Female118114232
Male153159312
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AnticoagulationAnticoagulation and EkoSonicTM Endovascular SystemTotal
Asian448
Black392362
Hispanic/Latino ethnic group8614
Native Hawaiian or other Pacific Islander246
White211232443
Unknown12618
Other347
08

Study locations

60 sites
09

References and documents

Publications

  • Barco S, Vicaut E, Klok FA, Lankeit M, Meyer G, Konstantinides SV; PEITHO Investigators. Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials. Eur Respir J. 2018 Jan 18;51(1):1701775. doi: 10.1183/13993003.01775-2017. Print 2018 Jan. No abstract available. PubMed 29348184 ↗
  • Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, Meyer G, Perrier A. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14. doi: 10.1093/eurheartj/ehu218. Epub 2014 Jun 10. PubMed 24917641 ↗
  • Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7. PubMed 26867832 ↗
  • Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011 Apr 26;123(16):1788-830. doi: 10.1161/CIR.0b013e318214914f. Epub 2011 Mar 21. PubMed 21422387 ↗
  • Becattini C, Agnelli G, Lankeit M, Masotti L, Pruszczyk P, Casazza F, Vanni S, Nitti C, Kamphuisen P, Vedovati MC, De Natale MG, Konstantinides S. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J. 2016 Sep;48(3):780-6. doi: 10.1183/13993003.00024-2016. Epub 2016 May 12. PubMed 27174887 ↗
  • Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galie N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-11. doi: 10.1056/NEJMoa1302097. PubMed 24716681 ↗
  • Bajaj NS, Kalra R, Arora P, Ather S, Guichard JL, Lancaster WJ, Patel N, Raman F, Arora G, Al Solaiman F, Clark DT 3rd, Dell'Italia LJ, Leesar MA, Davies JE, McGiffin DC, Ahmed MI. Catheter-directed treatment for acute pulmonary embolism: Systematic review and single-arm meta-analyses. Int J Cardiol. 2016 Dec 15;225:128-139. doi: 10.1016/j.ijcard.2016.09.036. Epub 2016 Sep 20. PubMed 27718446 ↗
  • Kucher N, Boekstegers P, Muller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, Tebbe U, Horstkotte J, Muller R, Blessing E, Greif M, Lange P, Hoffmann RT, Werth S, Barmeyer A, Hartel D, Grunwald H, Empen K, Baumgartner I. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014 Jan 28;129(4):479-86. doi: 10.1161/CIRCULATIONAHA.113.005544. Epub 2013 Nov 13. PubMed 24226805 ↗
  • Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM, Jones NJ, Gurley JC, Bhatheja R, Kennedy RJ, Goswami N, Natarajan K, Rundback J, Sadiq IR, Liu SK, Bhalla N, Raja ML, Weinstock BS, Cynamon J, Elmasri FF, Garcia MJ, Kumar M, Ayerdi J, Soukas P, Kuo W, Liu PY, Goldhaber SZ; SEATTLE II Investigators. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC Cardiovasc Interv. 2015 Aug 24;8(10):1382-1392. doi: 10.1016/j.jcin.2015.04.020. PubMed 26315743 ↗
  • Kuo WT, Banerjee A, Kim PS, DeMarco FJ Jr, Levy JR, Facchini FR, Unver K, Bertini MJ, Sista AK, Hall MJ, Rosenberg JK, De Gregorio MA. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): Initial Results From a Prospective Multicenter Registry. Chest. 2015 Sep;148(3):667-673. doi: 10.1378/chest.15-0119. PubMed 25856269 ↗
  • Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J, Maholic RL, Ross CB, Natarajan K, Fong P, Greenspon L, Tamaddon H, Piracha AR, Engelhardt T, Katopodis J, Marques V, Sharp ASP, Piazza G, Goldhaber SZ. A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial. JACC Cardiovasc Interv. 2018 Jul 23;11(14):1401-1410. doi: 10.1016/j.jcin.2018.04.008. PubMed 30025734 ↗
  • Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J. 2012 Jan;163(1):33-38.e1. doi: 10.1016/j.ahj.2011.10.003. PubMed 22172434 ↗
  • Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. No abstract available. PubMed 21670242 ↗
  • GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993 Sep 2;329(10):673-82. doi: 10.1056/NEJM199309023291001. PubMed 8204123 ↗
  • Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4. doi: 10.1111/j.1538-7836.2005.01204.x. PubMed 15842354 ↗
  • Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8. doi: 10.1016/j.echo.2010.05.010. No abstract available. PubMed 20620859 ↗
  • Liu VX, Lu Y, Carey KA, Gilbert ER, Afshar M, Akel M, Shah NS, Dolan J, Winslow C, Kipnis P, Edelson DP, Escobar GJ, Churpek MM. Comparison of Early Warning Scoring Systems for Hospitalized Patients With and Without Infection at Risk for In-Hospital Mortality and Transfer to the Intensive Care Unit. JAMA Netw Open. 2020 May 1;3(5):e205191. doi: 10.1001/jamanetworkopen.2020.5191. PubMed 32427324 ↗
  • Smith GB, Prytherch DR, Meredith P, Schmidt PE, Featherstone PI. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. Resuscitation. 2013 Apr;84(4):465-70. doi: 10.1016/j.resuscitation.2012.12.016. Epub 2013 Jan 4. PubMed 23295778 ↗
  • Quiroz R, Kucher N, Schoepf UJ, Kipfmueller F, Solomon SD, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation. 2004 May 25;109(20):2401-4. doi: 10.1161/01.CIR.0000129302.90476.BC. Epub 2004 May 17. PubMed 15148278 ↗
  • Stein PD, Matta F, Yaekoub AY, Goodman LR, Sostman HD, Weg JG, Hales CA, Hull RD, Leeper KV Jr, Beemath A, Saeed IM, Woodard PK. Reconstructed 4-chamber views compared with axial imaging for assessment of right ventricular enlargement on CT pulmonary angiograms. J Thromb Thrombolysis. 2009 Oct;28(3):342-7. doi: 10.1007/s11239-009-0331-5. Epub 2009 Mar 27. PubMed 19326189 ↗
  • ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available. PubMed 12091180 ↗
  • Klok FA, Cohn DM, Middeldorp S, Scharloo M, Buller HR, van Kralingen KW, Kaptein AA, Huisman MV. Quality of life after pulmonary embolism: validation of the PEmb-QoL Questionnaire. J Thromb Haemost. 2010 Mar;8(3):523-32. doi: 10.1111/j.1538-7836.2009.03726.x. Epub 2009 Dec 15. PubMed 20025645 ↗
  • Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. PubMed 1593914 ↗
  • Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016 Jan;41(1):206-32. doi: 10.1007/s11239-015-1310-7. PubMed 26780747 ↗
  • Cech DJ, Martin ST. Evaluation of function, activity, and participation. Functional Movement Development Across the Life Span (Third Edition), 2012.
  • Saris-Baglama RN, Dewey CJ, Chisholm GB, et al. QualityMetric health outcomes™ scoring software 4.0. Lincoln, RI: QualityMetric Incorporated, 2010, p. 138.
  • Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. No abstract available. PubMed 31504429 ↗
  • Rosenfield K, Klok FA, Piazza G, Sharp ASP, Ni Ainle F, Jaff MR, Barco S, Goldhaber SZ, Kucher N, Lang IM, Schmidtmann I, Sterling KM, Araszkiewicz A, Arora V, Cires-Drouet R, Coghlan J, Hobohm L, Ito WD, Jacobson K, Kaiser C, Kopec G, Marx K, McElwee S, Meneveau N, Monteleone P, Montero-Cabezas JM, Olivier CB, Park J, Roik M, Sakhuja R, Tego A, Theurl M, Visveswaran G, Vos JA, Young MN, Asch FM, Konstantinides SV; HI-PEITHO Investigators. Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism. N Engl J Med. 2026 May 28;394(20):1979-1990. doi: 10.1056/NEJMoa2516567. Epub 2026 Mar 28. PubMed 41910345 ↗
  • Klok FA, Piazza G, Sharp ASP, Ni Ainle F, Jaff MR, Chauhan N, Patel B, Barco S, Goldhaber SZ, Kucher N, Lang IM, Schmidtmann I, Sterling KM, Becker D, Martin N, Rosenfield K, Konstantinides SV. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. Am Heart J. 2022 Sep;251:43-53. doi: 10.1016/j.ahj.2022.05.011. Epub 2022 May 16. PubMed 35588898 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jul 2025, 47 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 24 phase 4 interventional studies under Pulmonary Embolism, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 82. This study's 47 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2021
First posted
Mar 10, 2021
StartActual
Aug 2, 2021
Primary completionActual
Jul 31, 2025
CompletionActual
Aug 18, 2026
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Results
Results posted
posted Nov 16, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedNumber of Participants With PE-related mortalityRelated MortalityTime frame: Within seven days of randomization
  • EditedNumber of Participants With Cardiorespiratory decompensationDecompensation or collapseCollapseTime frame: Within seven days of randomization
  • ChangedBefore PE recurrenceNow Number of Participants With Recurrent Pulmonary EmbolismTime frame: Within seven days of randomization
Nov 16, 2026
Documents
Secondary outcomes
17 edited, 2 added, 4 removed
What changed in the outcomes
  • Editedother outcomeChange From Baseline in the Right Ventricular-to-Left Ventricular (RV-to-LV diameter ratio as measured by echocardiography) Diameter RatioTime frame: Between baseline and 48±6 hours → Baseline and 48 hours after the index procedure
  • Editedother outcomeNumber of Participants With Cardiorespiratory decompensationDecompensationTime frame: Within 7 days → Within seven days of randomization
  • Editedother outcomeNumber of Participants With GUSTO majorMajor (moderate and severeModerate or Severe) bleedingBleedingTime frame: Within 7 days → Within seven days of randomization
  • Editedother outcomeNumber of Participants With International Society on Thrombosis and Hemostasis (ISTH) major bleedingMajor BleedingTime frame: Within 7 days, 30 days, and 6 months → Within 7 days, 30 days, and 6 months of randomization
  • Editedother outcomeNumber of Participants With Ischemic or hemorrhagic strokeHemorrhagic StrokeTime frame: Within 7 days and 30 days → Within 7 days and 30 days following randomization
  • Editedother outcomeNumber of Participants With All-cause mortalityCause MortalityTime frame: Within 7 days, 30 days, 6 months, and 12 months → Within 7 days, 30 days, 6 months, and 12 months of randomization
  • Editedother outcomeNumber of Participants With All-cause mortalityCause Mortality, cardiorespiratory collapseCardiorespiratory Collapse or recurrence of PEDecompensation, or Recurrent Pulmonary EmbolismTime frame: Within 30 days → Within 30 days of randomization
  • Editedother outcomeChange from baselineFrom Baseline in RV dysfunctionDysfunction on echocardiographyEchocardiographyTime frame: 6 months
  • Editedother outcomeDuration of hospitalizationHospitalization for the index PE eventIndex Pulmonary Embolism EventTime frame: Within 30 days → Within 30 days of randomization
  • Editedother outcomeDuration of stay atStay in the intensiveIntensive Care Unit (ICU), intermediateIntermediate Care Unit, or coronary care unit during hospitalizationCoronary Care Unit for the index PE eventIndex Pulmonary Embolism EventTime frame: Within 30 days → Within 30 days of randomization
  • Editedother outcomeFunctional statusStatus as measuredMeasured by World Health Organization (WHO) functional classFunctional ClassTime frame: Up to 7 days, 30 days, 6 and 12 months → Up to 7 days, 30 days, 6 and 12 months of randomization
  • Editedother outcomeFunctional statusStatus as measuredMeasured by 6-Minute Walk Test (6MWT)Time frame: 30 days, 6 and 12 months → 30 days, 6 months, and 12 months of randomization
  • Editedother outcomeFunctional statusStatus as measuredMeasured by Post-Venous Thromboembolism Functional Status (PVFS) scaleScaleTime frame: 30 days, 6 and 12 months → 30 days, 6 months, and 12 months of randomization
  • Editedother outcomeQuality of life usingLife Using PEmb-QOLTime frame: 6 and 12 months
  • Editedother outcomeQuality of life usingLife Using SF-36Time frame: 6 and 12 months
  • Editedother outcomeQuality of life usingLife Using EQ-5D scaleScaleTime frame: 6 and 12 months
  • Editedother outcomeDiagnosis of chronic thromboembolic pulmonary hypertensionChronic Thromboembolic Pulmonary Hypertension (CTEPH)Time frame: Within 12 months
  • Addedother outcomeNumber of Participants With at Least One Serious Adverse EventTime frame: Within 30 days of randomization
  • Addedother outcomeNumber of Participants With Symptomatic Recurrent Pulmonary EmbolismTime frame: Within 30 days and 6 months of randomization
  • Removedother outcomePE-related deathTime frame: Within 7 days
  • Removedother outcomePlacement on ECMO or mechanical ventilationTime frame: Within 7 days
  • Removedother outcomeSerious adverse eventsTime frame: Within 30 days
  • Removedother outcomeSymptomatic PE recurrenceTime frame: Within 30 days and 6 months
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Results posted
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedNumber of Participants With PE-related mortalityRelated MortalityTime frame: Within seven days of randomization
    • EditedNumber of Participants With Cardiorespiratory decompensationDecompensation or collapseCollapseTime frame: Within seven days of randomization
    • ChangedBefore PE recurrenceNow Number of Participants With Recurrent Pulmonary EmbolismTime frame: Within seven days of randomization
    Secondary outcomes 17 edited, 2 added, 4 removed
    What changed in the outcomes
    • Editedother outcomeChange From Baseline in the Right Ventricular-to-Left Ventricular (RV-to-LV diameter ratio as measured by echocardiography) Diameter RatioTime frame: Between baseline and 48±6 hours → Baseline and 48 hours after the index procedure
    • Editedother outcomeNumber of Participants With Cardiorespiratory decompensationDecompensationTime frame: Within 7 days → Within seven days of randomization
    • Editedother outcomeNumber of Participants With GUSTO majorMajor (moderate and severeModerate or Severe) bleedingBleedingTime frame: Within 7 days → Within seven days of randomization
    • Editedother outcomeNumber of Participants With International Society on Thrombosis and Hemostasis (ISTH) major bleedingMajor BleedingTime frame: Within 7 days, 30 days, and 6 months → Within 7 days, 30 days, and 6 months of randomization
    • Editedother outcomeNumber of Participants With Ischemic or hemorrhagic strokeHemorrhagic StrokeTime frame: Within 7 days and 30 days → Within 7 days and 30 days following randomization
    • Editedother outcomeNumber of Participants With All-cause mortalityCause MortalityTime frame: Within 7 days, 30 days, 6 months, and 12 months → Within 7 days, 30 days, 6 months, and 12 months of randomization
    • Editedother outcomeNumber of Participants With All-cause mortalityCause Mortality, cardiorespiratory collapseCardiorespiratory Collapse or recurrence of PEDecompensation, or Recurrent Pulmonary EmbolismTime frame: Within 30 days → Within 30 days of randomization
    • Editedother outcomeChange from baselineFrom Baseline in RV dysfunctionDysfunction on echocardiographyEchocardiographyTime frame: 6 months
    • Editedother outcomeDuration of hospitalizationHospitalization for the index PE eventIndex Pulmonary Embolism EventTime frame: Within 30 days → Within 30 days of randomization
    • Editedother outcomeDuration of stay atStay in the intensiveIntensive Care Unit (ICU), intermediateIntermediate Care Unit, or coronary care unit during hospitalizationCoronary Care Unit for the index PE eventIndex Pulmonary Embolism EventTime frame: Within 30 days → Within 30 days of randomization
    • Editedother outcomeFunctional statusStatus as measuredMeasured by World Health Organization (WHO) functional classFunctional ClassTime frame: Up to 7 days, 30 days, 6 and 12 months → Up to 7 days, 30 days, 6 and 12 months of randomization
    • Editedother outcomeFunctional statusStatus as measuredMeasured by 6-Minute Walk Test (6MWT)Time frame: 30 days, 6 and 12 months → 30 days, 6 months, and 12 months of randomization
    • Editedother outcomeFunctional statusStatus as measuredMeasured by Post-Venous Thromboembolism Functional Status (PVFS) scaleScaleTime frame: 30 days, 6 and 12 months → 30 days, 6 months, and 12 months of randomization
    • Editedother outcomeQuality of life usingLife Using PEmb-QOLTime frame: 6 and 12 months
    • Editedother outcomeQuality of life usingLife Using SF-36Time frame: 6 and 12 months
    • Editedother outcomeQuality of life usingLife Using EQ-5D scaleScaleTime frame: 6 and 12 months
    • Editedother outcomeDiagnosis of chronic thromboembolic pulmonary hypertensionChronic Thromboembolic Pulmonary Hypertension (CTEPH)Time frame: Within 12 months
    • Addedother outcomeNumber of Participants With at Least One Serious Adverse EventTime frame: Within 30 days of randomization
    • Addedother outcomeNumber of Participants With Symptomatic Recurrent Pulmonary EmbolismTime frame: Within 30 days and 6 months of randomization
    • Removedother outcomePE-related deathTime frame: Within 7 days
    • Removedother outcomePlacement on ECMO or mechanical ventilationTime frame: Within 7 days
    • Removedother outcomeSerious adverse eventsTime frame: Within 30 days
    • Removedother outcomeSymptomatic PE recurrenceTime frame: Within 30 days and 6 months
    + 3 other changes: verification date, date precision and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04790370
Collaborators
National PERT Consortium, Inc., University Medical Center Mainz
Responsible party
Sponsor
First posted
Mar 10, 2021
Start date
Aug 2, 2021
Primary completion
Jul 31, 2025
Completion
Aug 18, 2026
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Stavros Konstantinides, MD
principal investigator · University Medical Center Mainz, Mainz, Germany
Kenneth Rosenfield, MD
principal investigator · Massachusetts General Hospital, Boston, Massachusetts, USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion